吉林男科线医生专家(吉林细菌性前列腺炎可以治疗吗) (今日更新中)

The United States Consumer Product Safety Commission has issued a massive fire extinguisher recall that spans over 40 years and covers more than 120 models of fire extinguishers.According to the CPSC, it involves two styles of Kidde fire extinguishers: Plastic handle fire extinguishers and push button fire extinguishers. They may fail to discharge and the nozzle may detach.The 134 models were manufactured between Jan. 1, 1973 and Aug. 15, 2017, and includes models that have been previously recalled in March 2009 and February 2015.They were sold in red, white and silver and are either ABC- or BC-rated.According to the CPSC, there has been one death reported due to the recall. In 2014 emergency responders could not get the fire extinguishers to work during a car fire. There have also been 391 reports of failed or limited activation nozzle detachment, 16 injuries and 91 reports of property damage.They were sold at Menards, Montgomery Ward, Sears, The Home Depot, Walmart and other department, home and hardware stores across the country, and at Amazon.com.Consumers should contact Kidde to request a free replacement fire extinguisher.View the list of affected product codes below or by clicking here 1234

The US attorney based in Pittsburgh has started the process to seek the death penalty for the man accused of killing 11 worshippers at a synagogue Saturday, an assault during Shabbat services that reverberated across the country and around the world.On Monday, suspected gunman Robert Bowers was brought into federal court in a wheelchair for his first appearance. Wearing a blue shirt and handcuffs -- which US marshals removed so he could sign paperwork -- he spoke only to answer questions from the judge.The shooting struck the heart of historically Jewish Squirrel Hill and spurred sadness and anger as citizens learned the names of those gunned down by the killer."It's hard to understand how significant these losses are to our community unless you understand the significance and intimacy of Squirrel Hill," said Tree of Life congregant Jesse Rabner said."The community is knit so tight that one life affects thousands. It's a norm to be Jewish in Squirrel Hill, and it's a loving and peaceful community."Rabbi Hazzan Jeffrey Myers with Tree of Life said his synagogue will rebuild and "be back stronger and better than ever.""You can cut of some branches from our tree, but Tree of Life has been in Pittsburgh for 154 years. We're not going anywhere," the rabbi told CNN's "New Day" on Monday. "I will not let hate close down my building."Attorney General Jeff Sessions must ultimately give the OK to pursue the death penalty for the alleged gunman, Robert Bowers, the Justice Department said. The attack was the deadliest against Jews in US history."At this point in our investigation, we're treating it as a hate crime," Scott Brady, the US attorney for the Western District of Pennsylvania, said Sunday.When asked if the shooting could be considered an instance of domestic terrorism, Brady said there would need to be evidence the suspect tried to propagate a particular ideology through violence.In an address on Monday in Boston, Sessions labeled the assault a "murderous rampage" and said, "This was not just an attack on the Jewish faith. It was attack on all people of faith, and it was an attack on America's values of protecting those of faith. It cannot, it will not, be tolerated."Sessions said authorities will conduct the case "with vigor and integrity.""He'll be subjected to the death penalty perhaps," the attorney general said of the suspect.Bowers is expected back in court for a preliminary hearing Thursday morning. While two public defenders appeared with him in court Monday, the lawyer or lawyers who will handle his case going forward have yet to be appointed. He is being without bond.Brady will present the case to a federal grand jury within 30 days, he said.  2711

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The U.S. population grew by the smallest rate in at least 120 years from 2019 to 2020.Figures released Tuesday by the U.S. Census Bureau show the U.S. population grew by 0.35% from July 2019 to July 2020, an increase of 1.1 million people in a nation with an estimated population of more than 329 million residents.Demographer William Frey says population growth in the U.S. already had been stagnant over the past several years due to immigration restrictions and a dip in fertility.However, the pandemic exacerbated that lethargic-growth trend.Even during the height of the Spanish flu, the growth rate was higher — 0.49%. 632

The world has spent the last several months wearing masks in public, avoiding gatherings and, in general, spending less time outside the home. But a new report suggests household transmission is one of the most common ways COVID-19 is spreading; an individual is most likely to contract COVID-19 from their spouse or significant other.That conclusion is part of a new report from the University of Florida which was published in the journal JAMA Network Open on Monday. Researchers looked at the results of 54 studies across 20 countries that included nearly 78,000 subjects.They found more than one in three, roughly 38%, of COVID-19 patients passed the virus to their spouses or significant others they live with."Infection risk was highest for spouses, followed by non-spouse family members and other relatives, which were all higher than other [close] contacts," the authors wrote.In the studies, about 17% of COVID-19 patients transmitted the virus to children they live with.Anyone living in the same home as someone who has contracted the coronavirus is at a heightened risk, but researchers say spouses and significant others are more likely to pass along the virus for various reasons, including "intimacy, sleeping in the same room, or longer or more direct exposure to index cases," according to the report's authors.The researchers found no significant difference between male and female transmission rates inside the home.A recent study from the Centers for Disease Control and Prevention found that 53% of people who live with someone who has COVID-19 will contract the virus within seven days.Health experts have urged those who have COVID-19 or have symptoms to wear a mask in their home, and isolate within the home as much as possible away from others under the same roof. 1798

来源：资阳报